Gongwin Biopharm Holdings Co., Ltd. Announces Change of Directors
June 21, 2024 at 03:37 pm IST
Share
Gongwin Biopharm Holdings Co., Ltd. announced elected directors from the full election of Directors at the 2024 general shareholders meeting held on June 21, 2024. Title, name and nationality of the previous position holder: Director: Shao-Wen Gwo/R.O.C.; Director: Lie-Lin Zhan /R.O.C.; Director: Chi-HsiuLiu /R.O.C.; Independent Director: Wei-Da Cheng /R.O.C.; Independent Director: Zhi-Dong Yang /R.O.C. Resume of the previous position holder: Director: Shao-Wen Gwo /Director, Gongwin Biopharm Holdings Co., Ltd.; Director: Lie-Lin Zhan /
Deputy GM of Finance Department, YC INOX CO.,LTD.; Director: Chi-HsiuLiu /Chairman, Yizao Investment Co., Ltd.; Independent Director: Wei-Da Cheng /Independent Director, Gongwin Biopharm Holdings Co., Ltd.; Independent Director: Zhi-Dong Yang /Independent Director, Gongwin Biopharm Holdings Co., Ltd. Title, name and nationality of the new position holder: Director: Yi-LingHsieh /R.O.C.; Director: Shao-Feng Chien/R.O.C.; Independent Director: Jun-Yu Lin /R.O.C.; Independent Director: Cheng-Chi Liu /R.O.C.; Independent Director: Ching-JuWu /R.O.C. Resume of the new position holder: Director: Yi-LingHsieh /Purchasing Manager, MAKALOT INDUSTRIAL CO., LTD.; Director:Shao-Feng Chien /Accountant, FINTAXCPA; Independent Director: Jun-Yu Lin /Attending Physician, Department of Radiology, Yonghe Cardinal Tien Hospital; Independent Director: Cheng-Chi Liu /Chairman, MEDSAINT CO., LTD.; Independent Director: Ching-JuWu /Independent Director, Gongwin Biopharm Holdings Co., Ltd. Effective date of the new appointment: June 21, 2024.
Gongwin Biopharm Holdings Co Ltd is a company engaged in the research and development of anti-cancer medicine, especially focuses on the precise treatment to tumors. The Companyâs headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.
GONGWIN BIOPHARM HOLDINGS CO., LTD. 
